Neurim wins the battle but not (yet) the war for innovators
SCRIP Regulatory Affairs September 2012, 14-15Authors: Mike Snodin and Michael Pears
This article appeared in the September 2012 edition of SCRIP Regulatory Affairs. It explains the positive aspects that the innovative pharmaceutical industry will find in the Neurim decision. However, it also highlights the difficulties in understanding how broadly (and to whom) the decision can be applied, as well as the challenges to be faced by national patent offices and courts in squaring the Neurim decision with the prior case law of the Court of Justice. Back To List